Oct 8 (Reuters) – Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod drug in adults with Sjögren's disease, an autoimmune condition that damages the glands producing
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)